0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Editorial |

Uncovering the Risks of Immunosuppressive Therapy in Patients With Uveitis

Debra A. Goldstein, MD
Arch Ophthalmol. 2009;127(6):799-800. doi:10.1001/archophthalmol.2009.124.
Text Size: A A A
Published online

Extract

The systemic treatment of potentially blinding ocular inflammatory disease is fraught with challenges, ranging from lack of efficacy to serious safety concerns. Systemic corticosteroids, which have been used since the 1950s, have a host of potential adverse effects. Steroid-sparing agents such as methotrexate, azathioprine, and mycophenolate may reduce the need for corticosteroids, but carry with them their own set of adverse effects, and may be of limited efficacy in some cases. The biologic agents, including the tumor necrosis factor (TNF) inhibitors, have been more recently introduced and are being used with increasing frequency. The TNF inhibitor infliximab has been reported in case series and retrospective studies as effective in managing treatment-resistant ocular inflammation.13 Adverse effects have been reported as minimal in most series in the uveitis literature,35 but more significant in the rheumatologic literature.68 The adverse effect profile of infliximab, as with most agents, seems better with shorter reported follow-up.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

63 Views
4 Citations
×

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
brightcove.createExperiences();